Physicians' Academy for Cardiovascular Education

HDL as a risk marker and as a treatment target?

3' education - Nov. 1, 2011

HDL as a risk marker and as a treatment target?

Prof. Ulf Landmesser, Zurich and prof. John Deanfield, London are talking about good and bad cholesterol; HDL being the good cholesterol for years to the public. HDL might not always be good cholesterol. A big distinction has to be made between using HDL as a risk marker and as a treatment target; HDL cholesterol alone cannot be the treatment target. Each HDL targeted therapy has to be very carefully looked at.

It has to be investigated how to improve the anti-atherogenic functions of HDL. The HDL metabolism is very complex; the correct target within that metabolism has to be identified. HDL thus becomes very important as a new form of treatment compared to just lowering LDL cholesterol with statins.

Topics discussed in this PACE talk:

  • Why is HDL not always the good cholesterol?
  • CETP as HDL-targeted therapy – is it safe?
  • What did you see in patients with coronary artery disease?
  • Is raising HDL always beneficial? 
  • What is the most important information from dal-VESSEL?

View the slides

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: